logo-loader
viewArix Bioscience PLC

Arix Bioscience portfolio company Harpoon agrees US$2.4bn deal with Abbvie

For each of the targets, Harpoon will receive a milestone payment of $310mln each upfront plus royalties on global sales.

Arix Bioscience PLC -
This latest agreement builds on a collaboration deal signed in 2017 

Arix Bioscience PLC (LON:ARIX) portfolio company Harpoon Therapeutics (NASDAQ:HARP) has granted pharma giant Abbvie (NYSE:ABBV) an exclusive option over the rights to a treatment for a type of blood cancer.

The drug, HPN217, uses Harpoon’s Tri-specific T cell Activating Construct (TriTAC) technology to target BCMA, a biomarker associated with multiple myeloma cancer.

This latest agreement builds on a collaboration deal signed in 2017  and also gives Abbvie exclusive rights to develop and market two new TriTAC molecules plus an option to select up to four additional targets.

For each of the targets, Harpoon will receive a milestone payment of $310mln each upfront plus royalties on global sales.

Abbvie already has a drug in development for multiple myeloma but its progress has dogged by safety issues.

Harpoon will receive US$50mln upfront for the option over HPN217 and a further US$50mln when the first patient is treated in a clinical trial, though the licence and option agreement represents a potential transaction value of up to $510mln including royalties. 

Tritacs are a  group of T cell engagers that encourage the body’s own immune system to target both solid tumours and hematologic malignancies. 

Arix shares rose 2% to 113.5p.

Quick facts: Arix Bioscience PLC

Price: 112.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £152.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018

2 min read